

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	As of December 31,	
	2022	2021
	U.S. Dollars in thousands	
Assets		
<u>Current Assets</u>		
Cash and cash equivalents	\$ 34,258	\$ 18,587
Trade receivables, net	27,252	35,162
Other accounts receivables	8,710	8,872
Inventories	68,785	67,423
Total Current Assets	139,005	130,044
<u>Non-Current Assets</u>		
Property, plant and equipment, net	26,157	26,307
Right-of-use assets	2,568	3,092
Intangible assets, Goodwill and other long-term assets	147,072	153,663
Contract asset	7,577	5,561
Total Non-Current Assets	183,374	188,623
Total Assets	\$ 322,379	\$ 318,667
Liabilities		
<u>Current Liabilities</u>		
Current maturities of bank loans	\$ 4,444	\$ 2,631
Current maturities of lease liabilities	1,016	1,154
Current maturities of other long term liabilities	29,708	17,986
Trade payables	32,917	25,104
Other accounts payables	7,585	7,142
Deferred revenues	35	40
Total Current Liabilities	75,705	54,057
<u>Non-Current Liabilities</u>		
Bank loans	12,963	17,407
Lease liabilities	2,177	3,160
Contingent consideration	17,534	21,995
Other long-term liabilities	37,308	43,929
Deferred revenues	-	15
Employee benefit liabilities, net	672	1,280
Total Non-Current Liabilities	70,654	87,786
<u>Shareholder's Equity</u>		
Ordinary shares	11,734	11,725
Additional paid in capital net	210,495	210,204
Capital reserve due to translation to presentation currency	(3,490)	(3,490)
Capital reserve from hedges	(88)	54
Capital reserve from share-based payments	5,505	4,643
Capital reserve from employee benefits	348	(149)
Accumulated deficit	(48,484)	(46,163)
Total Shareholder's Equity	176,020	176,824
Total Liabilities and Shareholder's Equity	\$ 322,379	\$ 318,667

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	For the year ended		Three months period	
	December 31,		ended	
	2022	2021	2022	2021
	U.S. Dollars in thousands, other than per share information			
Revenues from proprietary products	\$ 102,598	\$ 75,521	\$ 35,400	\$ 18,205
Revenues from distribution	26,741	28,121	10,039	13,264
Total revenues	129,339	103,642	45,439	31,469
Cost of revenues from proprietary products	58,229	48,194	20,373	12,589
Cost of revenues from distribution	24,407	25,120	9,775	12,285
Total cost of revenues	82,636	73,314	30,148	24,874
Gross profit	46,703	30,328	15,291	6,595
Research and development expenses	13,172	11,357	2,991	3,448
Selling and marketing expenses	15,284	6,278	4,849	2,475
General and administrative expenses	12,803	12,636	3,322	3,833
Other expenses	912	753	111	141
Operating income (loss)	4,532	(696)	4,018	(3,302)
Financial income	91	295	59	18
Income (expenses) in respect of currency exchange differences and derivatives instruments, net	298	(207)	(458)	(281)
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.	(6,266)	-	(342)	-
Financial expenses	(914)	(1,277)	(331)	(1,099)
Income before tax on income	(2,259)	(1,885)	2,946	(4,664)
Taxes on income	62	345	2	345
Net Income (loss)	\$ (2,321)	\$ (2,230)	\$ 2,944	\$ (5,009)
Other Comprehensive Income (loss):				
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met				
Gain (loss) on cash flow hedges	(776)	-	54	(25)
Net amounts transferred to the statement of profit or loss for cash flow hedges	634	(303)	115	44
Items that will not be reclassified to profit or loss in subsequent periods:				
Remeasurement gain (loss) from defined benefit plan	497	171	136	171
Total comprehensive income (loss)	\$ (1,966)	\$ (2,362)	\$ 3,249	\$ (4,819)
<u>Earnings per share attributable to equity holders of the Company:</u>				
Basic net earnings per share	\$ (0.05)	\$ (0.05)	\$ 0.07	\$ (0.11)
Diluted net earnings per share	\$ (0.05)	\$ (0.05)	\$ 0.07	\$ (0.11)

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the year ended		Three months period	
	December 31,		ended	
	2022	2021	2022	2021
<u>Cash Flows from Operating Activities</u>				
Net income (loss)	\$ (2,321)	\$ (2,230)	\$ 2,944	\$ (5,009)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:				
Adjustments to the profit or loss items:				
Depreciation and impairment	12,155	5,609	3,012	1,997
Financial expenses (income), net	6,791	1,189	1,072	1,362
Cost of share-based payment	1,153	529	218	25
Taxes on income	62	345	2	345
Change in employee benefit liabilities, net	(111)	45	(5)	(16)
	<u>20,050</u>	<u>7,717</u>	<u>4,299</u>	<u>3,713</u>
Changes in asset and liability items:				
Decrease (increase) in trade receivables, net	7,603	(12,861)	(3,141)	(8,415)
Decrease (increase) in other accounts receivables	(578)	(1,634)	(3,495)	(3,191)
Decrease (increase) in inventories	(1,361)	(2,373)	4,245	3,590
Decrease (increase) in deferred expenses	(1,340)	(6,883)	1,256	(2,124)
Increase (decrease) in trade payables	7,055	7,917	1,160	5,192
Increase (decrease) in other accounts payables	290	(392)	(276)	1,091
Decrease in deferred revenues	(20)	1,815	(20)	265
	<u>11,649</u>	<u>(14,411)</u>	<u>(271)</u>	<u>(3,592)</u>
Cash received (paid) during the period for:				
Interest paid	(853)	(228)	(303)	(89)
Interest received	97	375	82	18
Taxes paid	(36)	(42)	(9)	(10)
	<u>(792)</u>	<u>105</u>	<u>(230)</u>	<u>81</u>
<u>Net cash provided by (used in) operating activities</u>	<u>\$ 28,586</u>	<u>\$ (8,819)</u>	<u>\$ 6,742</u>	<u>\$ (4,969)</u>

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the year ended		Three months period	
	December 31,		ended	
	2022	2021	2022	2021
U.S Dollars In thousands				
<u>Cash Flows from Investing Activities</u>				
Investment in short term investments, net	\$ -	\$ 39,083	\$ -	\$ -
Purchase of property and equipment and intangible assets	(3,784)	(3,730)	(977)	(744)
Business combination	-	(96,403)	-	(94,999)
Net cash provided by (used in) investing activities	<u>(3,784)</u>	<u>(61,050)</u>	<u>(977)</u>	<u>(95,743)</u>
<u>Cash Flows from Financing Activities</u>				
Proceeds from exercise of share base payments	9	19	2	5
Receipt of long-term loans	-	20,000	-	20,000
Repayment of lease liabilities	(1,098)	(1,221)	(256)	(318)
Repayment of long-term loans	(2,628)	(205)	(1,111)	16
Repayment of other long-term liabilities	(5,626)	-	(1,507)	-
Net cash provided by (used in) financing activities	<u>(9,343)</u>	<u>18,593</u>	<u>(2,872)</u>	<u>19,703</u>
Exchange differences on balances of cash and cash equivalent	<u>212</u>	<u>(334)</u>	<u>113</u>	<u>(244)</u>
Increase (decrease) in cash and cash equivalents	15,671	(51,610)	3006	(81,253)
<u>Cash and cash equivalents at the beginning of the period</u>	<u>18,587</u>	<u>70,197</u>	<u>31,252</u>	<u>99,840</u>
<u>Cash and cash equivalents at the end of the period</u>	<u>\$ 34,258</u>	<u>\$ 18,857</u>	<u>\$ 34,258</u>	<u>\$ 18,587</u>
<u>Significant non-cash transactions</u>				
Right-of-use asset recognized with corresponding lease liability	<u>\$ 551</u>	<u>\$ 845</u>	<u>\$ 526</u>	<u>\$ 76</u>
Purchase of property and equipment and Intangible assets	<u>\$ 618</u>	<u>\$ 1,001</u>	<u>\$ 134</u>	<u>\$ 649</u>

NON-IFRS MEASURES - EBITDA

	For the year ended		Three months period	
	December 31,		ended	
	2022	2021	2022	2021
	In thousands			
Net income	\$ (2,321)	\$ (2,230)	\$ 2,944	\$ (5,009)
Taxes on income	62	345	2	345
Financial expense (income), net	6,791	1,189	1,072	1,362
Depreciation and amortization expense	12,155	5,609	3,012	1,997
Non-cash share-based compensation expenses	1,153	529	218	25
Adjusted EBITDA	<u>\$ 17,840</u>	<u>\$ 5,442</u>	<u>\$ 7,248</u>	<u>\$ (1,280)</u>